A Phase 2 interventional study of palbociclib and Cetuximab in Squamous Cell Carcinoma of the Head and Neck (SCCHN), sponsored by Pfizer. Completed at 71 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-08.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Squamous Cell Carcinoma of Head and Neck by Pfizer — 3 open to participants now, 5 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · Pfizer.
Among the 30 studies in Squamous Cell Carcinoma of Head and Neck by Pfizer, this one is the 15th largest by enrollment, is one of 4 that started in 2015, is one of 6 in phase 2, and was the 6th registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →3 of the 30 studies in Squamous Cell Carcinoma of Head and Neck by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, China and 3 more countries
Ages 18+
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, Belgium, Canada and 8 more countries
Ages 18+
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, France, Korea, Republic of and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 10 · Phase 3 1
First in 2010; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 105 across the 30 interventional studies. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Squamous Cell Carcinoma of Head and Neck by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Squamous Cell Carcinoma of Head and Neck by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the combination of palbociclib with cetuximab is superior to cetuximab in prolonging overall survival in HPV-negative, cetuximab-naive patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Palbociclib, 125 mg, orally once daily (QD) with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
Drug: palbociclib · Drug: Cetuximab
Placebo orally QD with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
Drug: Cetuximab · Drug: Placebo
Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
Also known as: IBRANCE, PD-0332991
Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
Also known as: ERBITUX
Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death due to any cause. OS (in months) was calculated as (date of death - randomization date +1)/30.4. For participants lacking survival data beyond the date of their last follow-up, the OS time was censored on the last date they were known to be alive. Participants lacking survival data beyond randomization had their OS times be censored at randomization. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.
Time frame: Baseline up to primary completion date (PCD) (about 34 months)
Progression Free Survival (PFS)
PFS was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) or death due to any cause, whichever was earlier. Estimates of the PFS curves from the Kaplan Meier method were presented.
Time frame: Baseline up to PCD (about 34 months)
Percentage of Participants With Objective Response (OR)
OR was defined as the overall complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Objective response rate was defined as the proportion of participants with best overall response (BOR) of CR or PR relative to all randomized.
Time frame: Baseline up to PCD (about 34 months)
Percentage of Participants With Clinical Benefit Response (CBR)
CBR was defined as the overall CR, PR, or stable disease\>=24 weeks according to the RECIST version 1.1. Clinical benefit response rate was defined as the proportion of participants with CR, PR, or stable disease\>= 24 weeks relative to all randomized participants and randomized participants with measurable disease at baseline.
Time frame: Baseline up to PCD (about 34 months)
Duration of Response (DR)
DR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. DR was calculated as \[the date response ended (ie, date of PD or death) - first CR or PR date + 1\]/30.4.
Time frame: Baseline up to PCD (about 34 months)
Number of Participants With Treatment-Emergent Adverse Events(TEAEs)
AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. TEAEs were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. Severity was graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: From the first dose through and including 28 calendar days after the last administration of the study treatment (up to 6.9 years)
Number of Participants With Laboratory Abnormalities
The hematology, chemistry and coagulation tests were included in the laboratory examination. Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes. Chemistry evaluation included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen (BUN) or urea, creatinine, uric acid, glucose (non-fasted), albumin, phosphorus or phosphate and hemoglobin A1c (HbA1c). Coagulation evaluation included activated partial thromboplastin time/partial thromboplastin time, international normalized ratio (INR) or prothrombin time.
Time frame: From the Screening (Day -28) through and including 28 calendar days after the last administration of the study treatment (up to 7 years)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
The EORTC QLQ-C30 is a 30 item questionnaire composed of 5 multi-item functional subscales (physical, role, cognitive, emotional, and social functioning), 3 multi-item symptom scales (fatigue, nausea/vomiting, and pain), a global health/quality of life (QOL) subscale, and 6 single items assessing other cancer related symptoms (dyspnea, sleep disturbance, appetite, diarrhea, constipation, and the financial impact of cancer). The questionnaire employed twenty-eight 4 point Likert scales with responses from "not at all" to "very much" and two 7 point Likert scales for global health and overall QOL. For functional and global QOL scales, higher scores represented a better level of functioning and all scores were converted to a 0 to 100 scale. For symptom oriented scales, a higher score represented more severe symptoms, and all scores were converted to a 0-100 scale. Negative changes from baseline indicate deterioration in functioning / global QoL scales and improvement in symptom scales.
Time frame: Baseline up to PCD (about 34 months)
Change From Baseline in European Organization for Research and Treatment of Cancer Head and Neck Module35 (EORTC QLQ-H&N35)
The EORTC QLQ-H\&N35 is designed to be used together with the core QLQ-C30. The recall period for the items in the module was "the past week". Items hn1 to hn30 were scored on 4 point Likert type categorical scales ("not at all", "a little", "quite a bit", "very much"). Items hn31 to hn35 had a "no/yes" response format. The scores were transformed into 0 to 100 scales, with a high score implying a high level of symptoms.Negative changes from baseline indicate deterioration in functioning / global QoL scales and improvement in symptom scales.
Time frame: Baseline up to PCD (about 34 months)
Summary of PFS and OS for P16 Negative (%Positive Tumor Cells < 70%)
A central test was defined as the tumor tissue-based p16 IHC test performed at a central laboratory (Ventana). The analysis of concordance between HPV status as assessed by local or central laboratory included the number and percentage of participants with p16 detected or not detected at the central laboratory, given that all local testing must have been negative for HPV in order for the patient to be eligible for the study. Initial analysis of the p16 status was based on the conventional cutoff of 70% p16-positive tumor cells to call out cases that might be considered HPV-positive. P16 expression was scored as positive if strong and diffuse nuclear and cytoplasmic staining was present in at least 70% of the tumor cells.
Time frame: Screening
Summary of PFS and OS Based on Investigator Assessment by Rb Expression >= 1%
Rb expression in the palbociclib and cetuximab treatment group, the relationship of the biomarker (individually) with PFS and OS were explored using graphical methods such as box plots, at baseline. The tumors of participants were Rb-positive, which was defined by Rb IHC with\>=1% positive tumor cells.
Time frame: Screening
Trough Plasma Concentration (Ctrough) and Within-participant Mean Steady-state Pre-dose Concentration (WPM-Ctrough) at Steady State for Palbociblib
Ctrough is steady-state pre-dose concentration, which was observed directly from data. WPM-Ctrough is within-participant mean steady-state pre-dose concentration. For palbociclib, a steady-state trough was to be defined as a pre-dose plasma concentration following at least 7 consecutive days of 125 mg daily dose without dosing interruption and the time window for the PK collection was to be between 24 hr +/- 2 hr and 24 min post-dose the day prior to PK collection and no more than 1 hr post-dose on the day of PK collection.
Time frame: Pre-dose of Day 15 in Cycle 1 and Cycle 2
Ctrough and Cendinf, WPM-Ctrough and WPM-Cendinf at Steady State for Serum Cetuximab
Ctrough is steady-state pre-dose concentration. Cendinf is steady-state end-of-infusion concentration. Ctrough and Cendinf were observed directly from data. WPM-Ctrough and WPM-Cendinf are within-participant mean steady-state pre-dose concentration and end-of-infusion concentration. Acceptance criteria for a steady-state Cendinf was defined as a PK sample that was 1) collected after at least 3 consecutive weeks of cetuximab IV infusions without interruption or prior dose reduction and 2) was collected at the end of cetuximab infusion time +/- 10% of the actual duration of the cetuximab infusion.
Time frame: Pre-dose and end-of infusion of Day 15 in Cycle 1 and Cycle 2
| Milestone | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| Started | 65 | 60 |
| Received treatment | 64 | 60 |
| Completed | 0 | 0 |
| Not completed | 65 | 60 |
| Withdrew: Death | 52 | 43 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Participant refused further follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 5 |
| Withdrew: Other | 9 | 10 |
OS was defined as the time from the date of randomization to the date of death due to any cause. OS (in months) was calculated as (date of death - randomization date +1)/30.4. For participants lacking survival data beyond the date of their last follow-up, the OS time was censored on the last date they were known to be alive. Participants lacking survival data beyond randomization had their OS times be censored at randomization. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.
| months | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| Overall Survival (OS) | 9.7 (7.3 to 13.9) | 7.8 (6.7 to 10.6) |
PFS was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) or death due to any cause, whichever was earlier. Estimates of the PFS curves from the Kaplan Meier method were presented.
| months | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| Progression Free Survival (PFS) | 3.9 (3.6 to 5.6) | 4.6 (2.3 to 5.5) |
OR was defined as the overall complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Objective response rate was defined as the proportion of participants with best overall response (BOR) of CR or PR relative to all randomized.
| Percentage of participants | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| Percentage of Participants With Objective Response (OR) | 27.7 (17.3 to 40.2) | 25.0 (14.7 to 37.9) |
CBR was defined as the overall CR, PR, or stable disease\>=24 weeks according to the RECIST version 1.1. Clinical benefit response rate was defined as the proportion of participants with CR, PR, or stable disease\>= 24 weeks relative to all randomized participants and randomized participants with measurable disease at baseline.
| Percentage of participants | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| Percentage of Participants With Clinical Benefit Response (CBR) | 36.9 (25.3 to 49.8) | 36.7 (24.6 to 50.1) |
DR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. DR was calculated as \[the date response ended (ie, date of PD or death) - first CR or PR date + 1\]/30.4.
| months | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| Duration of Response (DR) | 7.6 (3.7 to 7.7) | 7.4 (3.6 to NA) |
AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. TEAEs were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. Severity was graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| Participants | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| AEs (all causality) | 61 | 56 |
| AEs (treatment-related) | 58 | 48 |
| SAEs (all causality) | 25 | 19 |
| SAEs (treatment-related) | 7 | 2 |
| Grade 3 or 4 AEs (all causality) | 33 | 19 |
| Grade 5 AEs (all causality) | 15 | 11 |
| Grade 3 or 4 AEs (treatment-related) | 34 | 10 |
| Grade 5 AEs (treatment-related) | 1 | 0 |
The hematology, chemistry and coagulation tests were included in the laboratory examination. Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes. Chemistry evaluation included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen (BUN) or urea, creatinine, uric acid, glucose (non-fasted), albumin, phosphorus or phosphate and hemoglobin A1c (HbA1c). Coagulation evaluation included activated partial thromboplastin time/partial thromboplastin time, international normalized ratio (INR) or prothrombin time.
| Participants | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| Number of Participants With Laboratory Abnormalities | 61 | 55 |
The EORTC QLQ-C30 is a 30 item questionnaire composed of 5 multi-item functional subscales (physical, role, cognitive, emotional, and social functioning), 3 multi-item symptom scales (fatigue, nausea/vomiting, and pain), a global health/quality of life (QOL) subscale, and 6 single items assessing other cancer related symptoms (dyspnea, sleep disturbance, appetite, diarrhea, constipation, and the financial impact of cancer). The questionnaire employed twenty-eight 4 point Likert scales with responses from "not at all" to "very much" and two 7 point Likert scales for global health and overall QOL. For functional and global QOL scales, higher scores represented a better level of functioning and all scores were converted to a 0 to 100 scale. For symptom oriented scales, a higher score represented more severe symptoms, and all scores were converted to a 0-100 scale. Negative changes from baseline indicate deterioration in functioning / global QoL scales and improvement in symptom scales.
| units on a scale | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| Global health status / QOL | 2.82 (-1.49 to 7.13) | 2.69 (-1.70 to 7.08) |
| Functional scale: Physical functioning | 0.74 (-3.26 to 4.73) | -0.46 (-4.59 to 3.66) |
| Functional scale: Role functioning | -0.41 (-5.91 to 5.09) | -1.60 (-7.28 to 4.08) |
| Functional scale: Emotional functioning | 4.16 (0.13 to 8.18) | 3.56 (-0.57 to 7.69) |
| Functional scale: Cognitive functioning | -1.47 (-5.14 to 2.21) | -1.23 (-5.06 to 2.59) |
| Functional scale: Social functioning | 1.24 (-4.43 to 6.90) | 2.08 (-3.76 to 7.92) |
| Symptom scale/item: Fatigue | -2.79 (-7.04 to 1.46) | -5.12 (-9.50 to -0.75) |
| Symptom scale/item: Nausea and vomiting | -0.87 (-2.63 to 0.90) | -1.04 (-2.82 to 0.74) |
| Symptom scale/item: Pain | -5.98 (-11.06 to -0.90) | -6.10 (-11.32 to -0.87) |
| Symptom scale/item: Dyspnoea | 3.07 (-2.15 to 8.30) | 5.09 (-0.27 to 10.45) |
| Symptom scale/item: Insomnia | -4.62 (-10.33 to 1.08) | -5.02 (-10.88 to 0.84) |
| Symptom scale/item: Appetite loss | 2.25 (-3.89 to 8.38) | -0.69 (-7.04 to 5.67) |
| Symptom scale/item: Constipation | -4.12 (-10.30 to 2.06) | -1.33 (-7.72 to 5.07) |
| Symptom scale/item: Diarrhoea | 4.26 (1.34 to 7.17) | 1.74 (-1.24 to 4.73) |
| Symptom scale/item: Financial difficulties | -5.26 (-11.61 to 1.10) | -0.27 (-6.83 to 6.29) |
The EORTC QLQ-H\&N35 is designed to be used together with the core QLQ-C30. The recall period for the items in the module was "the past week". Items hn1 to hn30 were scored on 4 point Likert type categorical scales ("not at all", "a little", "quite a bit", "very much"). Items hn31 to hn35 had a "no/yes" response format. The scores were transformed into 0 to 100 scales, with a high score implying a high level of symptoms.Negative changes from baseline indicate deterioration in functioning / global QoL scales and improvement in symptom scales.
| units on a scale | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| Symptom scale/item: Pain | -3.57 (-8.56 to 1.43) | -0.41 (-5.54 to 4.73) |
| Symptom scale/item: Swallowing | -4.34 (-8.79 to 0.10) | -1.47 (-6.03 to 3.09) |
| Symptom scale/item: Senses problems | -1.58 (-7.22 to 4.05) | -1.88 (-7.72 to 3.96) |
| Symptom scale/item: Speech problems | -4.54 (-9.21 to 0.13) | -2.69 (-7.51 to 2.13) |
| Symptom scale/item: Trouble with social eating | -5.55 (-10.14 to -0.96) | -0.71 (-5.42 to 4.01) |
| Symptom scale/item: Trouble with social contact | -1.27 (-5.68 to 3.15) | 3.45 (-1.14 to 8.04) |
| Symptom scale/item: Less sexuality | -3.32 (-11.44 to 4.80) | 4.90 (-3.72 to 13.53) |
| Symptom scale/item: Teeth | -1.59 (-8.91 to 5.74) | -1.88 (-9.29 to 5.53) |
| Symptom scale/item: Opening mouth | 0.35 (-5.29 to 5.99) | 0.22 (-5.56 to 5.99) |
| Symptom scale/item: Dry mouth | -6.30 (-10.50 to -2.10) | 3.44 (-0.82 to 7.71) |
| Symptom scale/item: Sticky saliva | -3.91 (-9.70 to 1.88) | 4.68 (-1.22 to 10.58) |
| Symptom scale/item: Coughing | -3.99 (-8.67 to 0.69) | -1.72 (-6.48 to 3.04) |
| Symptom scale/item: Felt ill | 1.320 (-4.22 to 6.86) | 0.12 (-5.45 to 5.70) |
| Symptom scale/item: Pain killers | -13.18 (-24.49 to -1.88) | -11.39 (-23.02 to 0.24) |
| Symptom scale/item: Nutritional supplements | 0.351 (-7.19 to 7.89) | -4.37 (-12.23 to 3.49) |
| Symptom scale/item: Feeding tube | -6.36 (-9.58 to -3.15) | -0.11 (-3.30 to 3.08) |
| Symptom scale/item: Weight loss | -17.72 (-27.23 to -8.21) | -9.47 (-19.16 to 0.22) |
| Symptom scale/item: Weight gain | -3.03 (-10.08 to 4.02) | 5.16 (-1.96 to 12.27) |
A central test was defined as the tumor tissue-based p16 IHC test performed at a central laboratory (Ventana). The analysis of concordance between HPV status as assessed by local or central laboratory included the number and percentage of participants with p16 detected or not detected at the central laboratory, given that all local testing must have been negative for HPV in order for the patient to be eligible for the study. Initial analysis of the p16 status was based on the conventional cutoff of 70% p16-positive tumor cells to call out cases that might be considered HPV-positive. P16 expression was scored as positive if strong and diffuse nuclear and cytoplasmic staining was present in at least 70% of the tumor cells.
| months | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| PFS | 3.7 (3.2 to 5.6) | 5.0 (3.3 to 7.2) |
| OS | 9.9 (7.1 to 13.9) | 8.0 (7.0 to 14.7) |
Rb expression in the palbociclib and cetuximab treatment group, the relationship of the biomarker (individually) with PFS and OS were explored using graphical methods such as box plots, at baseline. The tumors of participants were Rb-positive, which was defined by Rb IHC with\>=1% positive tumor cells.
| months | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| PFS | 3.9 (3.5 to 6.2) | 4.6 (2.6 to 5.6) |
| OS | 10.5 (7.1 to 15.6) | 7.8 (6.9 to 11.8) |
Ctrough is steady-state pre-dose concentration, which was observed directly from data. WPM-Ctrough is within-participant mean steady-state pre-dose concentration. For palbociclib, a steady-state trough was to be defined as a pre-dose plasma concentration following at least 7 consecutive days of 125 mg daily dose without dosing interruption and the time window for the PK collection was to be between 24 hr +/- 2 hr and 24 min post-dose the day prior to PK collection and no more than 1 hr post-dose on the day of PK collection.
| nanograms per milliliter (ng/ml) | Palbociclib + Cetuximab |
|---|---|
| Ctrough Cycle 1 Day 15 | 69.8 ± 28.208 |
| Ctrough Cycle 2 Day 15 | 67.8 ± 28.905 |
| WPM-Ctrough | 71.6 ± 30.183 |
Ctrough is steady-state pre-dose concentration. Cendinf is steady-state end-of-infusion concentration. Ctrough and Cendinf were observed directly from data. WPM-Ctrough and WPM-Cendinf are within-participant mean steady-state pre-dose concentration and end-of-infusion concentration. Acceptance criteria for a steady-state Cendinf was defined as a PK sample that was 1) collected after at least 3 consecutive weeks of cetuximab IV infusions without interruption or prior dose reduction and 2) was collected at the end of cetuximab infusion time +/- 10% of the actual duration of the cetuximab infusion.
| ng/ml | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| Ctrough Cycle 1 Day 15 | 39706.4 ± 92 | 42914.1 ± 62 |
| Ctrough Cycle 2 Day 15 | 51005.3 ± 74 | 52995.7 ± 71 |
| WPM-Ctrough | 45605.9 ± 83 | 46796.5 ± 63 |
| Cendinf Cycle 1 Day 15 | 145748.3 ± 43 | 137185.5 ± 61 |
| Cendinf Cycle 2 Day 15 | 149155.7 ± 38 | 153310.1 ± 39 |
| WPM-Cendinf | 149119.2 ± 36 | 148063.3 ± 39 |
Collected over From the first dose through and including 28 calendar days after the last administration of the study treatment (up to 6.9 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Palbociclib + Cetuximab | 52/64 (81.3%) | 25/64 (39.1%) | 55/64 (85.9%) |
| Placebo + Cetuximab | 43/60 (71.7%) | 19/60 (31.7%) | 53/60 (88.3%) |
| Event | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| Disease progressionGeneral disorders | 7/64 | 6/60 |
| PneumoniaInfections and infestations | 4/64 | 0/60 |
| SepsisInfections and infestations | 0/64 | 2/60 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/64 | 2/60 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/64 | 0/60 |
| AnaemiaBlood and lymphatic system disorders | 0/64 | 1/60 |
| Duodenal ulcer haemorrhageGastrointestinal disorders | 0/64 | 1/60 |
| DysphagiaGastrointestinal disorders | 0/64 | 1/60 |
| NauseaGastrointestinal disorders | 0/64 | 1/60 |
| Anaphylactic reactionImmune system disorders | 0/64 | 1/60 |
| Event | Palbociclib + Cetuximab | Placebo + Cetuximab |
|---|---|---|
| RashSkin and subcutaneous tissue disorders | 27/64 | 21/60 |
| AnaemiaBlood and lymphatic system disorders | 23/64 | 8/60 |
| NeutropeniaBlood and lymphatic system disorders | 19/64 | 0/60 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 14/64 | 13/60 |
| LeukopeniaBlood and lymphatic system disorders | 13/64 | 0/60 |
| Decreased appetiteMetabolism and nutrition disorders | 12/64 | 10/60 |
| White blood cell count decreasedInvestigations | 11/64 | 0/60 |
| HypomagnesaemiaMetabolism and nutrition disorders | 11/64 | 8/60 |
| Platelet count decreasedInvestigations | 10/64 | 0/60 |
| DiarrhoeaGastrointestinal disorders | 9/64 | 5/60 |
Baseline analysis population included all participants who were randomized.
| Age, Continuous(years) | Palbociclib + Cetuximab | Placebo + Cetuximab | Total |
|---|---|---|---|
| Mean | 58.3 ± 10.2 | 60.9 ± 10.1 | 59.5 ± 10.2 |
| Sex: Female, Male(Participants) | Palbociclib + Cetuximab | Placebo + Cetuximab | Total |
|---|---|---|---|
| Female | 8 | 4 | 12 |
| Male | 57 | 56 | 113 |
| Race/Ethnicity, Customized(Participants) | Palbociclib + Cetuximab | Placebo + Cetuximab | Total |
|---|---|---|---|
| White | 47 | 46 | 93 |
| Black | 1 | 1 | 2 |
| Asian | 15 | 13 | 28 |
| Other | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2015 to primary completion in Jul 2018, 34 months.
Results were first posted in Sep 2019, 1 year 2 months after primary completion.
Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 34 months is below that.
Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palbociclib
Squamous Cell Carcinoma of Head and Neck →